Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia.
Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia.
复制标题
DOI：
10.3389/fcvm.2021.769472
复制
发表时间：
2021
影响因子：
3.6
通讯作者：
Dong Z
中科院分区：
文献类型：
--
作者：
Jiang X;Liu H;Pan T;Gu S;Fang Y;Wei Z;Fang G;Chen B;Jiang J;Shi Y;Liu P;Fu W;Dong Z
背景资料：在初步研究中，外周血单个核细胞（PBMNCs）在治疗血管炎诱导的无选择严重肢体威胁性缺血（AICLTI）中显示出令人鼓舞的短期结果。本研究旨在证明这种治疗的长期结果。研究方法：对2014年5月至2018年12月在我中心确诊为AICLTI并接受自体外周血单个核细胞移植治疗的患者进行入组分析。主要终点为无大截肢生存率（MAFS），次要终点包括峰值无痛步行时间（PPFWT）、Wong-Baker FACES疼痛评定量表评分（WFPRSS）、分娩恢复、踝臂指数（ABI）、经皮血氧分压（TcpO 2）和SF-36 v2评分。结果：共纳入58例患者。最短随访36个月，MAFS为93.1%，劳动能力恢复率为62.1%。WFPRSS评分从8.7 ± 1.6降至1.6 ± 3.2，PPFWT从2.9 ± 4.2 min降至16.6 ± 6.9 min，生活质量在各随访时间点均有显著改善。灌注评价指标ABI、TcPO 2也明显改善。在治疗和随访期间未观察到严重不良事件。结论：自体外周血单个核细胞移植治疗AICLTI显示出令人鼓舞的长期结果。不仅能恢复劳动能力，提高生活质量，而且能明显降低大截肢率。
Background: Peripheral blood mononuclear cells (PBMNCs) showed encouraging short outcomes in the treatment of angiitis-induced no-option critical limb-threatening ischemia (AICLTI) in the pilot study. This study aimed to demonstrate the long-term outcomes of this treatment. Methods: From May 2014 to December 2018, patients diagnosed with AICLTI and treated by autotransplantation of PBMNCs in our center were enrolled and analyzed. The primary endpoint was major amputation-free survival (MAFS), the secondary endpoints included peak pain-free walking time (PPFWT), Wong-Baker FACES pain rating scale score (WFPRSS), labor recovery, ankle-brachial index (ABI), transcutaneous partial oxygen pressure (TcpO2), and SF-36v2 scores. Results: A total of 58 patients were enrolled. During a minimal follow-up of 36 months, the MAFS was 93.1% and the labor competence restored rate was 62.1%. The WFPRSS was decreased from 8.7 ± 1.6 to 1.6 ± 3.2, and PPFWT was significantly improved from 2.9 ± 4.2 min to 16.6 ± 6.9 min. The quality of life was also significantly improved at each follow-up point. Perfusion evaluating parameters, such as ABI and TcPO2, were also significantly improved. No critical adverse event was observed during the treatment and follow-up period. Conclusions: The treatment of AICLTI by autotransplantation of PBMNCs demonstrated encouraging long-term results. It could not only restore labor competence, improve the quality of life, but also significantly reduce the major amputation rate.
登录
查看更多内容
影响因子：
56.9
作者：
Asahara, T;Murohara, T;Isner, JM
通讯作者：
Isner, JM
影响因子：
4.3
作者：
Dong, Zhihui;Chen, Bin;Mendelsohn, Farrell Owen
通讯作者：
Mendelsohn, Farrell Owen
影响因子：
3.3
作者：
Hoshino, Junichi;Ubara, Yoshifumi;Takaichi, Kenmel
通讯作者：
Takaichi, Kenmel
影响因子：
12.4
作者：
Mäkinen, K;Manninen, H;Ylä-Herttuala, S
通讯作者：
Ylä-Herttuala, S
DOI：
10.1161/circinterventions.112.968321
发表时间：
2012-12
期刊：
Circulation. Cardiovascular interventions
影响因子：
--
作者：
Losordo DW;Kibbe MR;Mendelsohn F;Marston W;Driver VR;Sharafuddin M;Teodorescu V;Wiechmann BN;Thompson C;Kraiss L;Carman T;Dohad S;Huang P;Junge CE;Story K;Weistroffer T;Thorne TM;Millay M;Runyon JP;Schainfeld R;Autologous CD34+ Cell Therapy for Critical Limb Ischemia Investigators
通讯作者：
Autologous CD34+ Cell Therapy for Critical Limb Ischemia Investigators